0

Close
 
Upcoming Allied Market Research
2023
Fusion Protein And Biosimilars Market

Fusion Protein and Biosimilars Market

by Product Type (Cytokines Recombinant Protein, Immunoglobin (Ig) Fusion Protein, Parathyroid Hormone (PTPH) Fusion Protein, Others), by Application (Cancer, HIV-AIDS, Respiratory Disease, Cardiovascular Disorder, Ophthalmology, Others) and by End User (Hospitals, Research Institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A12017
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Fusion Protein And Biosimilars Market

Request Now !

A fusion protein biosimilars have come out as a new modality, as an alternate of biologic products due to their high cost. The fusion protein biosimilars merge the modified pharmacological properties of biological ligands, together with multiple functions of the fragmented crystallizable domain of immunoglobulins. The fusion protein biosimilars are utilized in various clinical studies based on applications like HIV-AIDS, cancer, chronic inflammatory diseases, and many other chronic diseases. So many applications of fusion protein biosimilars have raised their demand in the global market. Thus, the increase in prevalence of such chronic diseases anticipates surge in demand for biosimilars in the market.

COVID-19 Impact analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the fusion protein biosimilars market.

Top Impacting Factors

  • Increase in incidence of chronic diseases, surge in demand for cost-effective treatment options, expansion of the healthcare infrastructure, government initiatives, rise in number of approvals, and product launches are anticipated to fuel the growth of the fusion protein biosimilars market.
  • The wide range of applications of fusion protein biosimilar in many chronic diseases like HIV-AIDS, chronic inflammatory disorders, cardiovascular disorder, cancer, and beneficial insurance along with FDA approval pathway for cost reductions projects to obtain high patient entry is the key factor projected to propel the growth of the fusion protein biosimilars market
  • The regulatory approvals of faster-developing biosimilars indicate a notable change in the industry and the potential for severe drops in profits for pharmaceutical companies along with growing research efforts and in-pipeline drugs look for better opportunities for the fusion protein biosimilars market growth in the coming years.
  • Difficult analytical characterization due to complex structure, associated side effects with prescribed drugs, stringent regulatory approvals, and time-consuming factors for clinical studies are expected to hinder the fusion protein biosimilars market growth.

Market Trends

New product launches to flourish the market

In January 2020, Coherus BioSciences, Inc. came into a licensing agreement with Innovent Biologics, (Suzhou) Co., Ltd., a major Chinese biopharmaceutical company, in order to commercialize biosimilar candidates to Avastin (bevacizumab) in North American countries like U.S and Canada.

In September 2018, SOTIO acquired Cytune Pharma. This agreement was signed to permit the company the utilization of Cytune’s SO-C101, a human fusion protein of IL-15 along with their autologous dendritic cell therapy platform DCVAC based clinical programs in lung, prostate, and ovarian cancer.

Surge in usage in chronic disease treatment

The fusion protein biosimilars are utilized in several clinical studies of HIV AIDS, cancer, chronic inflammatory diseases, and many other chronic diseases. The increase in prevalence of such chronic diseases and various applications of fusion protein biosimilars have increased their demand in the global market. Cancer expects to hold a higher share in the fusion protein biosimilars market due to increase in number of cancer cases among the growing population in the world.

Key Benefits of the Report

  • This study presents the analytical depiction of the fusion protein biosimilars industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the fusion protein biosimilars market share.
  • The current market is quantitatively analyzed to highlight the fusion protein biosimilars market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed fusion protein biosimilars market analysis based on competitive intensity and how the competition will take shape in coming years

Questions answered in the fusion protein biosimilars Report

  • What is "Fusion protein biosimilars"?
  • What is "Fusion protein biosimilars" Market prediction in the future?
  • Who are the leading global players in the "Fusion protein biosimilars" Market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "Fusion protein biosimilars" Market report?                                                                                                                                                                                                                             

 Fusion Protein and Biosimilars Market Report Highlights

Aspects Details
By Product Type
  • Cytokines Recombinant Protein
  • Immunoglobin (Ig) Fusion Protein
  • Parathyroid Hormone (PTPH) Fusion Protein
  • Others
By Application
  • Cancer
  • HIV-AIDS
  • Respiratory Disease
  • Cardiovascular Disorder
  • Ophthalmology
  • Others
By End User
  • Hospitals
  • Research Institutes
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Samsung Bioepis, Novartis AG, Dr. Reddy’s Laboratories Ltd., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Mylan N.V., Pfizer Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: FUSION PROTEIN AND BIOSIMILARS MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Cytokines Recombinant Protein

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Immunoglobin (Ig) Fusion Protein

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Parathyroid Hormone (PTPH) Fusion Protein

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: FUSION PROTEIN AND BIOSIMILARS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Cancer

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. HIV-AIDS

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Respiratory Disease

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Cardiovascular Disorder

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Ophthalmology

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Others

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: FUSION PROTEIN AND BIOSIMILARS MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Research Institutes

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

  • CHAPTER 7: FUSION PROTEIN AND BIOSIMILARS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product Type

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Fusion Protein And Biosimilars Market

        • 7.2.6.1. Market Size and Forecast, By Product Type
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Fusion Protein And Biosimilars Market

        • 7.2.7.1. Market Size and Forecast, By Product Type
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Fusion Protein And Biosimilars Market

        • 7.2.8.1. Market Size and Forecast, By Product Type
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product Type

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Fusion Protein And Biosimilars Market

        • 7.3.6.1. Market Size and Forecast, By Product Type
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Fusion Protein And Biosimilars Market

        • 7.3.7.1. Market Size and Forecast, By Product Type
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Fusion Protein And Biosimilars Market

        • 7.3.8.1. Market Size and Forecast, By Product Type
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Fusion Protein And Biosimilars Market

        • 7.3.9.1. Market Size and Forecast, By Product Type
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Fusion Protein And Biosimilars Market

        • 7.3.10.1. Market Size and Forecast, By Product Type
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Fusion Protein And Biosimilars Market

        • 7.3.11.1. Market Size and Forecast, By Product Type
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Fusion Protein And Biosimilars Market

        • 7.3.12.1. Market Size and Forecast, By Product Type
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product Type

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Fusion Protein And Biosimilars Market

        • 7.4.6.1. Market Size and Forecast, By Product Type
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Fusion Protein And Biosimilars Market

        • 7.4.7.1. Market Size and Forecast, By Product Type
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Fusion Protein And Biosimilars Market

        • 7.4.8.1. Market Size and Forecast, By Product Type
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Fusion Protein And Biosimilars Market

        • 7.4.9.1. Market Size and Forecast, By Product Type
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Fusion Protein And Biosimilars Market

        • 7.4.10.1. Market Size and Forecast, By Product Type
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Fusion Protein And Biosimilars Market

        • 7.4.11.1. Market Size and Forecast, By Product Type
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Fusion Protein And Biosimilars Market

        • 7.4.12.1. Market Size and Forecast, By Product Type
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Fusion Protein And Biosimilars Market

        • 7.4.13.1. Market Size and Forecast, By Product Type
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Fusion Protein And Biosimilars Market

        • 7.4.14.1. Market Size and Forecast, By Product Type
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product Type

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Fusion Protein And Biosimilars Market

        • 7.5.6.1. Market Size and Forecast, By Product Type
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Fusion Protein And Biosimilars Market

        • 7.5.7.1. Market Size and Forecast, By Product Type
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Fusion Protein And Biosimilars Market

        • 7.5.8.1. Market Size and Forecast, By Product Type
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Fusion Protein And Biosimilars Market

        • 7.5.9.1. Market Size and Forecast, By Product Type
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Fusion Protein And Biosimilars Market

        • 7.5.10.1. Market Size and Forecast, By Product Type
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Fusion Protein And Biosimilars Market

        • 7.5.11.1. Market Size and Forecast, By Product Type
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Novartis AG

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Pfizer Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Eli Lilly And Company

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Sandoz International GmbH

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. F. Hoffmann-La Roche Ltd.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. AbbVie Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Dr. Reddy’s Laboratories Ltd.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Samsung Bioepis

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Teva Pharmaceutical Industries Ltd.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Mylan N.V.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR CYTOKINES RECOMBINANT PROTEIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR IMMUNOGLOBIN (IG) FUSION PROTEIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR PARATHYROID HORMONE (PTPH) FUSION PROTEIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR HIV-AIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR RESPIRATORY DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR CARDIOVASCULAR DISORDER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA FUSION PROTEIN AND BIOSIMILARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. U.S. FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. U.S. FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. CANADA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. CANADA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE FUSION PROTEIN AND BIOSIMILARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. ITALY FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. UK FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. UK FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. UK FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 50. RUSSIA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. RUSSIA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC FUSION PROTEIN AND BIOSIMILARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. CHINA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. CHINA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. CHINA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. JAPAN FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. INDIA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 66. INDIA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. INDIA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. AUSTRALIA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 75. THAILAND FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. THAILAND FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 78. MALAYSIA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 79. MALAYSIA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 81. INDONESIA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 82. INDONESIA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA FUSION PROTEIN AND BIOSIMILARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. LAMEA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 91. BRAZIL FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 92. BRAZIL FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 97. SAUDI ARABIA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 98. SAUDI ARABIA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. UAE FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 100. UAE FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 101. UAE FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 103. ARGENTINA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 104. ARGENTINA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA FUSION PROTEIN AND BIOSIMILARS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 106. REST OF LAMEA FUSION PROTEIN AND BIOSIMILARS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 107. REST OF LAMEA FUSION PROTEIN AND BIOSIMILARS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 108. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 109. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 110. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 111. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 112. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. PFIZER INC.: KEY EXECUTIVES
  • TABLE 114. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 115. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 116. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 117. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 119. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 120. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 121. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 122. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. SANDOZ INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 124. SANDOZ INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 125. SANDOZ INTERNATIONAL GMBH: OPERATING SEGMENTS
  • TABLE 126. SANDOZ INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 127. SANDOZ INTERNATIONAL GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 129. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 130. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 131. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 132. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 134. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 135. ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 136. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 137. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 139. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 140. DR. REDDY’S LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 141. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 142. DR. REDDY’S LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. SAMSUNG BIOEPIS: KEY EXECUTIVES
  • TABLE 144. SAMSUNG BIOEPIS: COMPANY SNAPSHOT
  • TABLE 145. SAMSUNG BIOEPIS: OPERATING SEGMENTS
  • TABLE 146. SAMSUNG BIOEPIS: PRODUCT PORTFOLIO
  • TABLE 147. SAMSUNG BIOEPIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 149. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 150. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 151. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 152. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. MYLAN N.V.: KEY EXECUTIVES
  • TABLE 154. MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 155. MYLAN N.V.: OPERATING SEGMENTS
  • TABLE 156. MYLAN N.V.: PRODUCT PORTFOLIO
  • TABLE 157. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL FUSION PROTEIN AND BIOSIMILARS MARKET
  • FIGURE 3. SEGMENTATION FUSION PROTEIN AND BIOSIMILARS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN FUSION PROTEIN AND BIOSIMILARS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALFUSION PROTEIN AND BIOSIMILARS MARKET
  • FIGURE 11. FUSION PROTEIN AND BIOSIMILARS MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. FUSION PROTEIN AND BIOSIMILARS MARKET FOR CYTOKINES RECOMBINANT PROTEIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. FUSION PROTEIN AND BIOSIMILARS MARKET FOR IMMUNOGLOBIN (IG) FUSION PROTEIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. FUSION PROTEIN AND BIOSIMILARS MARKET FOR PARATHYROID HORMONE (PTPH) FUSION PROTEIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. FUSION PROTEIN AND BIOSIMILARS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. FUSION PROTEIN AND BIOSIMILARS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 17. FUSION PROTEIN AND BIOSIMILARS MARKET FOR CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. FUSION PROTEIN AND BIOSIMILARS MARKET FOR HIV-AIDS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. FUSION PROTEIN AND BIOSIMILARS MARKET FOR RESPIRATORY DISEASE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. FUSION PROTEIN AND BIOSIMILARS MARKET FOR CARDIOVASCULAR DISORDER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. FUSION PROTEIN AND BIOSIMILARS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. FUSION PROTEIN AND BIOSIMILARS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. FUSION PROTEIN AND BIOSIMILARS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 24. FUSION PROTEIN AND BIOSIMILARS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. FUSION PROTEIN AND BIOSIMILARS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: FUSION PROTEIN AND BIOSIMILARS MARKET
  • FIGURE 32. Top player positioning, 2022
  • FIGURE 33. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. ELI LILLY AND COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. SANDOZ INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. SANDOZ INTERNATIONAL GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. SANDOZ INTERNATIONAL GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. ABBVIE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. ABBVIE INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. DR. REDDY’S LABORATORIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. SAMSUNG BIOEPIS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. SAMSUNG BIOEPIS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. SAMSUNG BIOEPIS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. MYLAN N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. MYLAN N.V.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Fusion Protein And Biosimilars Market

Start reading.
This Report and over 66,782+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers